Bioanalytical  ||| S:0 E:14 ||| JJ
advances  ||| S:14 E:23 ||| NNS
in  ||| S:23 E:26 ||| IN
assays  ||| S:26 E:33 ||| NN
for  ||| S:33 E:37 ||| IN
C-reactive  ||| S:37 E:48 ||| JJ
protein  ||| S:48 E:56 ||| NN
This  ||| S:56 E:61 ||| DT
review  ||| S:61 E:68 ||| NN
presents  ||| S:68 E:77 ||| VBZ
advances  ||| S:77 E:86 ||| NNS
in  ||| S:86 E:89 ||| IN
assays  ||| S:89 E:96 ||| NN
for  ||| S:96 E:100 ||| IN
human  ||| S:100 E:106 ||| JJ
C-reactive  ||| S:106 E:117 ||| JJ
protein  ||| S:117 E:125 ||| NN
( ||| S:125 E:126 ||| -LRB-
CRP ||| S:126 E:129 ||| NNP
) ||| S:129 E:130 ||| -RRB-
,  ||| S:130 E:132 ||| ,
the  ||| S:132 E:136 ||| DT
most  ||| S:136 E:141 ||| RBS
important  ||| S:141 E:151 ||| JJ
biomarker  ||| S:151 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
infection  ||| S:164 E:174 ||| NN
and  ||| S:174 E:178 ||| CC
inflammation  ||| S:178 E:191 ||| NN
for  ||| S:191 E:195 ||| IN
a  ||| S:195 E:197 ||| DT
plethora  ||| S:197 E:206 ||| NN
of  ||| S:206 E:209 ||| IN
diseases  ||| S:209 E:218 ||| NNS
and  ||| S:218 E:222 ||| CC
pathophysiological  ||| S:222 E:241 ||| JJ
conditions ||| S:241 E:251 ||| NNS
.  ||| S:251 E:253 ||| .
Routine  ||| S:253 E:261 ||| JJ
assays  ||| S:261 E:268 ||| NN
in  ||| S:268 E:271 ||| IN
clinical  ||| S:271 E:280 ||| JJ
settings  ||| S:280 E:289 ||| NNS
are  ||| S:289 E:293 ||| VBP
based  ||| S:293 E:299 ||| VBN
on  ||| S:299 E:302 ||| IN
analyzers ||| S:302 E:311 ||| NN
,  ||| S:311 E:313 ||| ,
enzyme-linked  ||| S:313 E:327 ||| JJ
immunosorbent  ||| S:327 E:341 ||| JJ
assays  ||| S:341 E:348 ||| NN
and  ||| S:348 E:352 ||| CC
lateral  ||| S:352 E:360 ||| JJ
flow  ||| S:360 E:365 ||| NN
assays ||| S:365 E:371 ||| NN
.  ||| S:371 E:373 ||| .
However ||| S:373 E:380 ||| RB
,  ||| S:380 E:382 ||| ,
assays  ||| S:382 E:389 ||| FW
encompassing  ||| S:389 E:402 ||| FW
novel  ||| S:402 E:408 ||| FW
sensing  ||| S:408 E:416 ||| FW
schemes ||| S:416 E:423 ||| FW
,  ||| S:423 E:425 ||| ,
improved  ||| S:425 E:434 ||| JJ
chemistry ||| S:434 E:443 ||| NN
,  ||| S:443 E:445 ||| ,
signal  ||| S:445 E:452 ||| NN
enhancement ||| S:452 E:463 ||| NN
,  ||| S:463 E:465 ||| ,
lab-on-a-chip ||| S:465 E:478 ||| NNP
,  ||| S:478 E:480 ||| ,
microfluidics  ||| S:480 E:494 ||| NN
and  ||| S:494 E:498 ||| CC
smartphone  ||| S:498 E:509 ||| JJ
detection ||| S:509 E:518 ||| NN
,  ||| S:518 E:520 ||| ,
have  ||| S:520 E:525 ||| VBP
emerged  ||| S:525 E:533 ||| VBN
in  ||| S:533 E:536 ||| IN
recent  ||| S:536 E:543 ||| JJ
years ||| S:543 E:548 ||| NNS
.  ||| S:548 E:550 ||| .
The  ||| S:550 E:554 ||| DT
incorporation  ||| S:554 E:568 ||| NN
of  ||| S:568 E:571 ||| IN
immune-transducing  ||| S:571 E:590 ||| JJ
chips  ||| S:590 E:596 ||| NNS
or  ||| S:596 E:599 ||| CC
sensing  ||| S:599 E:607 ||| JJ
interfaces  ||| S:607 E:618 ||| NN
with  ||| S:618 E:623 ||| IN
nanomaterials  ||| S:623 E:637 ||| NN
enables  ||| S:637 E:645 ||| VBZ
multiplexing  ||| S:645 E:658 ||| JJ
analysis  ||| S:658 E:667 ||| NN
of  ||| S:667 E:670 ||| IN
CRP  ||| S:670 E:674 ||| NNP
with  ||| S:674 E:679 ||| IN
co-existing  ||| S:679 E:691 ||| JJ
biomarkers ||| S:691 E:701 ||| NN
.  ||| S:701 E:703 ||| .
However ||| S:703 E:710 ||| RB
,  ||| S:710 E:712 ||| ,
there  ||| S:712 E:718 ||| EX
are  ||| S:718 E:722 ||| VBP
still  ||| S:722 E:728 ||| RB
considerable  ||| S:728 E:741 ||| JJ
challenges  ||| S:741 E:752 ||| NNS
in  ||| S:752 E:755 ||| IN
the  ||| S:755 E:759 ||| DT
development  ||| S:759 E:771 ||| NN
of  ||| S:771 E:774 ||| IN
rapid  ||| S:774 E:780 ||| JJ
diagnostics  ||| S:780 E:792 ||| NNS
for  ||| S:792 E:796 ||| IN
both  ||| S:796 E:801 ||| DT
pentameric  ||| S:801 E:812 ||| NN
and  ||| S:812 E:816 ||| CC
monomeric  ||| S:816 E:826 ||| JJ
CRP  ||| S:826 E:830 ||| NN
forms ||| S:830 E:835 ||| NNS
.  ||| S:835 E:837 ||| .
